

Synonym

CLEC2D, C-type lectin domain family 2 member D, Lectin-like NK cell receptor, Lectin-like transcript 1, LLT-1, Osteoclast inhibitory lectin

Source

Human CLEC2D, Mouse IgG2a Fc Tag(CLD-H5253) is expressed from human 293 cells (HEK293). It contains AA Arg 60 - Val 191 (Accession # [Q9UHP7-1](#)). Predicted N-terminus: Glu

Molecular Characterization

mFc(Glu 98 - Lys 330) P01863	CLEC2D(Arg 60 - Val 191) Q9UHP7-1
---------------------------------	--------------------------------------

This protein carries a mouse IgG2a Fc tag at the N-terminus

The protein has a calculated MW of 42.2 kDa. The protein migrates as 45-55 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 0.1 EU per µg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

Formulation

Lyophilized from 0.22 µm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage


For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:


- 20°C to -70°C for 12 months in lyophilized state;
- 70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human CLEC2D, Mouse IgG2a Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS



The purity of Human CLEC2D, Mouse IgG2a Fc Tag (Cat. No. CLD-H5253) is more than 90% and the molecular weight of this protein is around 95-110 kDa verified by SEC-MALS.

[Report](#)

Background

CLEC2D (C-type lectin domain family 2 member D) is also known as CLAX, LLT1, OCIL is receptor for KLRB1 that protects target cells against natural killer cell-mediated lysis, inhibits osteoclast formation, inhibits bone resorption and modulates the release of interferon-gamma. It is also a ligand for the human NKR-P1A (CD161) receptor, present on NK cells and T cells. Furthermore, The reference shows the pathway may as a potential immunotherapy targets.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.